Abstract
A growing problem of major proportions had been confronting biomedical scientists for many decades. Until solved, this long-neglected problem, the abject failure of the American health care system, presents a gigantic obstacle to the application of the discoveries flowing from neuropsychopharmacological research into deliverable medications utilized by medical practitioners. Although it is recognized that such advances could benefit all of society, both in the United States and globally, progress toward this important goal has not happened. As I noted 5 years ago, ‘Unless steps are taken soon to undertake a comprehensive restoration of our system, the profound advances in bio-medical research so rapidly accruing today may never be effectively transformed into meaningful advances in health care for society.’ I remain perplexed and frustrated by the reluctance of scientific research societies such as our ACNP to engage their energies and intellect into this most serious issue.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abelson R, Freudenheim M (2008). Even the insured feel strain of health costs. In: New York Times. 4 May 2008.
Adams K, Corrigan JM (eds) (2003). Priority Areas for National Action: Transforming Health Care Quality. National Academy Press: Washington, DC.
Aiken LH, Clarke SP, Sloane DM, Sochalski J, Silber JH (2002). Hospital nurse staffing and patient mortality, nurse burnout, and job dissatisfaction. JAMA 288: 1987–1993.
Anton RF (2008). Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics 9: 655–658.
Blendon RJ, Altman DE, Deane C, Benson JM, Brodie M, Buhr T (2008). Health care in the 2008 presidential primaries. N Engl J Med 358: 414–422.
Bloom FE (2003). Presidential address. Science as a way of life: perplexities of a physician–scientist. Science 300: 1680–1685.
Committee on Quality of Health Care in America, IoM (2001). Crossing the Quality Chasm: A New Health System for the 21st Century. National Academy Press: Washington, DC.
Education, ACGME. (2002). Report of the Working Group on Resident Duty Hours and the Learning Environment. http://www.acgme.org/acWebsite/dutyhours/dh_wdex.asp, accessed 9/25/08.
Garbutt JC (2006). Medications for the treatment of alcohol dependence. Am Fam Physician 74: 1836.
Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL et al. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293: 1617–1625.
http://clinicaltrials.gov/ct2/show/NCT00606476?term=bapineuzumab&rank=6,(2008).
http://www.brokenpipeline.org/,(2008). Compendium of 7 academic centers efforts to restore NIH funding increments.
Kohn LT, Corrigan JM, Donaldson MS . (eds). (2000). To Err is Human: Building a Safer Health System. National Academy Press: Washington, DC.
Ludmerer KM (1999). Time to Heal, Vol., Oxford University Press: New York.
Murillo H, Reece EA, Snyderman R, Sung NS (2006). Meeting the challenges facing clinical research: solutions proposed by leaders of medical specialty and clinical research societies. Acad Med 81: 107–112.
Nathan D (2002). Careers in translational clinical research—historical perspectives, future challenges. JAMA 287: 2424–2427.
O'Kane M, Corrigan J, Foote SM, Tunis SR, Isham GJ, Nichols LM et al. (2008). Crossroads in quality. Health Aff (Millwood) 27: 749–758.
Sonnert G, Holton G (2002). Ivory Bridges, Vol., MIT Press: Cambridge, MA.
Sung NS, Crowley Jr WF, Genel M, Salber P, Sandy L, Sherwood LM et al. (2003). Central challenges facing the national clinical research enterprise. JAMA 289: 1278–1287.
Williams M (2003). Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia. Curr Opin Investig Drugs 4: 31–36.
Author information
Authors and Affiliations
Corresponding author
Additional information
DISCLOSURE/CONFLICT OF INTEREST
The author is a director of Alkermes Inc., Cambridge, MA, and a director of Elan Pharmaceuticals, Dublin, Ireland.
Rights and permissions
About this article
Cite this article
Bloom, F. Commentary: Physician–Scientist's Frustrations Fester. Neuropsychopharmacol 34, 1–5 (2009). https://doi.org/10.1038/npp.2008.181
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2008.181
